The Federal Government Just Funded Psychedelic Research at Scale. ARPA-H's $139 Million EVIDENT Program Changes Everything.

Johns Hopkins is running eight psilocybin trials. The University of Wisconsin is studying whether the psychedelic experience itself matters or whether the neurobiological mechanism alone drives therapeutic benefit. Diamond Therapeutics is testing psilocybin for generalized anxiety disorder. Yale is investigating pregnenolone for alcohol use disorder. And the federal government is paying for all of it.

On April 21, 2026, the Advanced Research Projects Agency for Health announced the first thirteen research teams selected for EVIDENT — Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health. The initiative will fund up to $139.4 million in research aimed at solving the fundamental measurement problem that has held back psychiatric treatment for decades: how do you objectively measure whether a mental health therapy actually works?

At least $50 million of that total is earmarked specifically for psychedelic research, designated to match state government investments under President Trump's Executive Order to Accelerate Medical Treatments for Serious Mental Illness. The federal government has funded psychedelic studies before, in small doses through NIH and the VA. But EVIDENT represents something categorically different — a coordinated, heavily resourced federal program that treats psychedelics not as fringe science but as a mainstream therapeutic frontier requiring rigorous clinical infrastructure.

For researchers, biotech companies, digital health startups, and academic medical centers working in behavioral health, this is the largest federal funding commitment to the field in a generation.

The Measurement Problem EVIDENT Is Designed to Solve

Psychiatric medicine operates with a measurement deficit that would be unacceptable in any other branch of clinical science. Oncologists measure tumor size. Cardiologists measure ejection fraction. Psychiatrists ask patients to fill out questionnaires.

The reliance on subjective self-report instruments — the PHQ-9 for depression, the GAD-7 for anxiety, the AUDIT for alcohol use — creates cascading problems for drug development. Clinical trials are expensive because subjective endpoints require larger sample sizes to reach statistical significance. FDA approval pathways are uncertain because regulators cannot easily distinguish placebo response from genuine therapeutic effect. And payers resist covering new treatments because the evidence base rests on instruments that even their creators acknowledge are imprecise.

EVIDENT attacks this problem directly. The program is organized around four technical areas, each targeting a different facet of objective measurement:

Technical Area 1 focuses on developing objective measurement tools — biomarkers, wearable sensor data, neuroimaging signatures, and physiological indicators that can quantify behavioral health states without relying on patient self-report.

Technical Area 2 investigates treatment mechanisms. For psychedelics specifically, this means answering the question that has divided the field: does psilocybin work because of the subjective psychedelic experience, or because of downstream neuroplasticity effects that could theoretically be achieved without the trip?

Technical Area 3 develops predictive models for treatment response — tools that could tell a clinician before starting treatment whether a given patient is likely to respond to psilocybin, neuromodulation, or a digital therapeutic.

Technical Area 4 builds shared data infrastructure across all teams, ensuring that the biomarker data, clinical outcomes, and measurement tools developed under EVIDENT are interoperable and reusable for future research.

The structure is deliberate. ARPA-H is not funding thirteen independent studies. It is funding a coordinated measurement ecosystem that, if successful, could reshape how the entire behavioral health field conducts clinical trials and seeks regulatory approval.

The Thirteen Teams and What They Are Building

The selected teams span academic medical centers, biotech companies, and digital health startups. The portfolio reveals ARPA-H's bet on where objective measurement breakthroughs will come from:

Psychedelic-focused teams:

• Johns Hopkins University School of Medicine is contributing data from eight psilocybin clinical trials — the largest single-institution psychedelic dataset in the world. Their role in EVIDENT is to identify objective biomarkers that predict and track psilocybin treatment response across multiple conditions.
• University of Wisconsin is analyzing data from three approved psilocybin trials alongside vagus nerve stimulation studies. Their central research question — whether conscious psychedelic experience or non-conscious neurobiological mechanisms drive therapeutic benefit — could fundamentally change how psychedelic therapies are designed and delivered.
• University of Southern California is studying psilocybin with and without mindfulness training, testing whether the therapeutic context modifies the neurobiological response.
• Diamond Therapeutics (Toronto), partnering with the Tactical Mind Research Coalition, is contributing Phase 2a clinical trial data on psilocybin for generalized anxiety disorder.

Biomarker and measurement teams:

• Duke University is developing objective stress physiology markers using cortisol, estradiol, and interleukin measurements — the kind of blood-based biomarkers that could serve as psychiatric equivalents to the hemoglobin A1C test in diabetes.
• Alden Scientific (Cambridge, MA) is applying multi-omics analysis to behavioral health, searching for molecular signatures of treatment response.
• INVI MindHealth (Denver) is building a real-time biomarker platform that augments neuromodulation and psychedelic therapy research with objective, continuous measurement during treatment sessions.
• Ksana Health (Eugene, OR) is integrating wearable device data to capture behavioral and physiological signals outside the clinical setting.

Neuromodulation and novel intervention teams:

• Attune Neurosciences (San Francisco) is developing low-intensity focused ultrasound neuromodulation — a non-invasive brain stimulation approach that could complement or substitute for psychedelic therapy.
• Motif Neurotech (Houston) is collecting neuromodulation data to build predictive models of treatment response.

Population-scale and systems teams:

• NeuroFlow (Philadelphia) is evaluating interventions at population scale — the kind of large-sample analysis needed to move psychiatric measurement from research novelty to clinical standard.
• Holobiome (Boston) is investigating the gut-brain axis, developing microbiome-modulating interventions that target stress physiology through an entirely different biological pathway.
• Yale Stress Center is testing pregnenolone for alcohol use disorder, representing the non-psychedelic rapid-acting therapeutic approach within the EVIDENT portfolio.

The Executive Order Connection and the $50 Million State Match

EVIDENT does not exist in a policy vacuum. It implements a specific directive from President Trump's Executive Order to Accelerate Medical Treatments for Serious Mental Illness, which instructed ARPA-H to catalyze research into rapid-acting therapies including psychedelics.

The at-least-$50-million allocation for psychedelic research is structured as a state matching program. States that invest their own funds in psychedelic research for populations with serious mental illness can access federal matching dollars through EVIDENT. This design creates a powerful incentive mechanism: states already moving on psychedelic policy — Oregon legalized psilocybin services in 2023, Colorado in 2024, and over a dozen states have introduced legislation — now have a federal partner willing to co-invest.

The matching structure also insulates the program politically. Federal funds flow to match state decisions, distributing accountability and making it harder for any single congressional critic to characterize the spending as a federal overreach. For an administration that has simultaneously cut NIH funding by billions, the psychedelic carve-out represents a remarkably specific and durable policy commitment.

The broader ARPA-H context matters too. The agency has now launched 31 programs and supports nearly 150 projects. EVIDENT joins PROSPR (aging/longevity, $144 million), CIRCLE (critical illness), and other large-scale initiatives in demonstrating that ARPA-H has moved past its startup phase into sustained program execution. With HHS Secretary Robert F. Kennedy Jr. publicly championing psychedelic medicine, ARPA-H's behavioral health portfolio has executive-level protection that few other federal research programs enjoy right now.

Who Should Apply for the Next Round

ARPA-H has stated that future awards under EVIDENT will be made on a rolling basis. The first thirteen teams are not the last. The program is explicitly designed to expand as new measurement approaches and therapeutic candidates emerge.

The strongest candidates for future EVIDENT funding will have several characteristics:

Objective measurement capability. EVIDENT is not funding clinical trials for their own sake. Every project must advance the development of objective endpoints — biomarkers, sensor-derived metrics, imaging signatures, or molecular indicators — that could replace or supplement self-report instruments. If your research generates subjective outcome data only, EVIDENT is not the right program.

Data contribution. The shared data infrastructure (Technical Area 4) is central to EVIDENT's design. Teams that can contribute large, well-characterized clinical datasets — particularly from psychedelic, neuromodulation, or digital therapeutic trials — will have a natural advantage. The Johns Hopkins selection, with its eight-trial psilocybin dataset, illustrates this principle.

Interdisciplinary teams. The selected portfolio mixes psychiatrists, neuroscientists, bioengineers, data scientists, and device developers. ARPA-H is not looking for single-investigator R01-style proposals. It is looking for teams that can bridge the gap between biological measurement and clinical application.

Regulatory pathway awareness. The ultimate goal of EVIDENT is to produce FDA-ready clinical endpoints. Teams that understand the regulatory landscape — what FDA has accepted, what it has rejected, and what evidentiary standards apply to psychiatric drug approvals — will write more competitive proposals than those focused purely on scientific novelty.

For small businesses, ARPA-H also offers SBIR/STTR awards with higher caps than most agencies: up to $600,000 for Phase 1 and $3.5 million for Phase 2. Companies developing measurement devices, digital biomarkers, wearable sensors, or computational tools for behavioral health assessment should examine both EVIDENT and the ARPA-H SBIR program.

What This Means for the Behavioral Health Field

EVIDENT's significance extends beyond the $139 million in direct funding. If the program succeeds in producing validated objective endpoints for psychiatric treatment, it will reduce the cost and increase the predictability of every subsequent clinical trial in behavioral health. Drug developers, medical device companies, digital therapeutics firms, and academic medical centers will all benefit from a shared measurement infrastructure that does not currently exist.

The psychedelic research component carries particular weight. The FDA rejected MDMA-assisted therapy for PTSD in 2024 partly because of concerns about functional unblinding in clinical trials — participants could tell whether they received the active drug, contaminating self-report outcomes. Objective biomarkers that measure therapeutic response independently of the subjective experience could resolve this regulatory barrier for the entire class of psychedelic-assisted therapies.

The federal investment also sends a market signal. Venture capital funding for psychedelic therapeutics has declined since the FDA rejection, with investors questioning whether subjective endpoints could ever satisfy regulatory requirements. EVIDENT answers that question by funding the measurement tools that make rigorous, approvable clinical trials possible.

ARPA-H anticipates rolling announcements for additional EVIDENT teams. Researchers and companies working at the intersection of behavioral health, biomarker development, and rapid-acting therapeutics should monitor the ARPA-H open funding opportunities page for new solicitations. Tools like Granted can help you identify when those opportunities open and build a competitive application before deadlines close.